Literature DB >> 12086242

Guidelines for managing Alzheimer's disease: Part II. Treatment.

Jeffrey L Cummings1, Janet C Frank, Debra Cherry, Neal D Kohatsu, Bryan Kemp, Linda Hewett, Brian Mittman.   

Abstract

Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed. This plan should include cholinesterase inhibitor therapy to temporarily improve cognition or slow the rate of cognitive decline, management of comorbid conditions, treatment of behavioral symptoms and mood disorders, provision of support and resources for patient and caregiver, and compliance with state-mandated reporting requirements for driving impairment and elder abuse. The primary caregiver can be a valuable ally in communication, management of care, and implementation of the care plan. Patient symptoms and care needs change as Alzheimer's disease progresses. In the early stage of the disease, the family physician should discuss realistic expectations for drug therapy, solicit patient and family preferences on future care choices, and assist with advance planning for future care challenges. In the middle stage, the patient may exhibit behavioral symptoms that upset the caregiver and are difficult to manage. When the patient is in the advanced stage of Alzheimer's disease, the caregiver may need support to provide for activities of daily living, help in making a difficult placement decision, and guidance in considering terminal care options. Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086242

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  27 in total

1.  The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.

Authors:  Grace Wu; Krista L Lanctôt; Nathan Herrmann; Shehnaz Moosa; Paul I Oh
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.

Authors:  Carl H Sadowsky; Joseph L Micca; George T Grossberg; Drew M Velting
Journal:  Prim Care Companion CNS Disord       Date:  2014-09-04

3.  Rapid cognitive decline in Alzheimer's disease. Consensus paper.

Authors:  M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

4.  Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Authors:  Dong-Churl Suh; Stephen Arcona; Simu K Thomas; Christopher Powers; Adrian L Rabinowicz; Hyunchul Shin; Dario Mirski
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.

Authors:  Dong-Churl Suh; Simu K Thomas; Elmira Valiyeva; Stephen Arcona; Lien Vo
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Practice constraints, behavioral problems, and dementia care: primary care physicians' perspectives.

Authors:  Ladson Hinton; Carol E Franz; Geetha Reddy; Yvette Flores; Richard L Kravitz; Judith C Barker
Journal:  J Gen Intern Med       Date:  2007-09-07       Impact factor: 5.128

Review 7.  Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.

Authors:  David B Hogan; Peter Bailey; Sandra Black; Anne Carswell; Howard Chertkow; Barry Clarke; Carole Cohen; John D Fisk; Dorothy Forbes; Malcolm Man-Son-Hing; Krista Lanctôt; Debra Morgan; Lilian Thorpe
Journal:  CMAJ       Date:  2008-11-04       Impact factor: 8.262

8.  Treatment advances in Alzheimer's disease based on the oxidative stress model.

Authors:  Avi L Friedlich; Raj K Rolston; Xiongwei Zhu; Michael W Marlatt; Rudy J Castellani; Akihiko Nunomura; Hyoung-Gon Lee; Gemma Casadesus; George Perry; Mark A Smith
Journal:  F1000 Med Rep       Date:  2009-07-08

9.  Primary care providers' views of challenges and rewards of dementia care relative to other conditions.

Authors:  Dorothy P Harris; Joshua Chodosh; Stefanie D Vassar; Barbara G Vickrey; Martin F Shapiro
Journal:  J Am Geriatr Soc       Date:  2009-11-23       Impact factor: 5.562

10.  Family physicians' perspectives on care of dementia patients and family caregivers.

Authors:  Mark J Yaffe; Pam Orzeck; Lucy Barylak
Journal:  Can Fam Physician       Date:  2008-07       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.